132112-35-7

基本信息
(S)-1-丙基-2',6'-二甲基苯胺甲酰基哌啶单盐酸盐一水合物
(s)-罗哌卡因盐酸盐
(-)-S)-N-(2,6-二甲基苯基)-1-正丙基哌啶-2-甲酰胺盐酸盐
盐酸罗哌卡因
ROPIVACAINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
ROPIVCACAINE HYDROCHLORIDE
S-ROPIVACAINE HCL
(S)-ROPIVACAINE HYDROCHLORIDE
(S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine monohydrochloride monohydrate
(S)-1-propyl-2',6'-dimethylanilinoformoxylpiperidine,monohydrochloride,monohydrate
(S)-Ropivaxaine hydrochloride
(S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
Ropivacaine hydrochloride
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide Hydrochloride Hydrate
LEA-103
物理化学性质
熔点 | 267-269°C |
比旋光度 | D20 -7.28° (c = 2 in water) |
储存条件 | 2-8°C |
溶解度 | H2O:可溶5mg/mL,澄清 |
形态 | 粉末 |
颜色 | 白色至灰白色 |
旋光性 (optical activity) | [α]/D -9 to -12, c = 1 in methanol |
水溶解性 | H2O: 5mg/mL, clear |
InChI | InChI=1/C17H26N2O.ClH.H2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;;/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H;1H2/t15-;;/s3 |
InChIKey | VSHFRHVKMYGBJL-CKUXDGONSA-N |
SMILES | [C@H]1(CCCCN1CCC)C(=O)NC1=C(C)C=CC=C1C.O.Cl |&1:0,r| |
CAS 数据库 | 132112-35-7(CAS DataBase Reference) |
安全数据
危险性符号(GHS) | ![]() GHS05 |
警示词 | 危险 |
危险性描述 | H318 |
防范说明 | P280-P305+P351+P338 |
危险品标志 | T,Xi |
危险类别码 | 26/27/28-41 |
安全说明 | 22-36/37/39-45-39-26 |
危险品运输编号 | UN 2811 6.1 / PGIII |
WGK Germany | 3 |
海关编码 | 2933399090 |
常见问题列表
外科手术麻醉
-----硬膜外麻醉,包括剖宫产术
-----蛛网膜下腔麻醉
-----区域阻滞
急性疼痛控制
-----持续硬膜外输注或间歇性单次用药,如术后或阴道分娩镇痛
-----区域阻滞
盐酸罗哌卡因的一般副作用有低血压、恶心、心动过缓、焦虑、感觉减退。
IC50: sodium ion influxIC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)
Ropivacaine HCl是一种局部麻醉剂。Ropivacaine HCl通过可逆抑制神经纤维中钠离子流引起神经阻滞。Ropivacaine HCl的pKa是~8.2。Ropivacaine HCl在高血浆浓度下具有诱导心血管毒性和CNS毒性的可能性。
Epidural administration of Ropivacaine hydrochloride monohydrate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine hydrochloride monohydrate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
Ropivacaine hydrochloride monohydrate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.
Animal Model: | Adult Sprague-Dawley rats (300–400g) |
Dosage: | 1 μM |
Administration: | Infusion (added to the perfusate reservoir) |
Result: | Attenuated pressure-dependent increases in filtration coefficient (K f ). |
盐酸罗哌卡因一水合物价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-B0563B | 盐酸罗哌卡因 Ropivacaine hydrochloride | 132112-35-7 | 5 mg | 218元 |
2025/02/08 | HY-B0563B | 盐酸罗哌卡因 Ropivacaine hydrochloride | 132112-35-7 | 10mM * 1mLin DMSO | 239元 |
2025/02/08 | HY-B0563B | 盐酸罗哌卡因 Ropivacaine hydrochloride | 132112-35-7 | 10 mg | 350元 |